Samsung, Merck Look To Take On Sanofi’s Lantus With Latest Deal
This article was originally published in PharmAsia News
Executive Summary
In the latest win for Samsung Bioepis, the Korean company will help develop and manufacture a late-stage insulin glargine candidate with Merck.
You may also be interested in...
Sanofi Fires Up Late-Stage R&D After Growth Rekindled in Fourth Quarter
Nine late-stage products are expected to lead Sanofi’s future evolution into a developer primarily of biologics, including alirocumab for hypercholesterolemia, dupilumab for atopic dermatitis and asthma, and sarilumab for rheumatoid arthritis.
Asia Spotlight: China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.
China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.